Table 3.

Analysis of the FDA-approved compounds from the DrugCentral database with a predicted hERG pIC₅₀ value above 7.0

Drug Name	Pharmacological Indication	Mechanism of Action	FDA Approval Status	Predicted hERG pIC50	In Training Set	Experimentally Determined hERG pIC50
Nintedanib	Idiopathic pulmonary fibrosis	Kinase inhibitor	Approved	8.234	yes	8.585
Ibutilide	Atrial fibrillation, atrial flutter	hERG channel blocker	Approved	7.977	yes	8.000
Pimozide	Tourette’s disorder	Dopamine D2 receptor antagonist	Approved	7.629	yes	8.520
Halofantrine	Severe malaria	Forms toxic complexes with ferritoporphyrin IX	Approved	7.588	no	7.398
Astemizole	Allergy symptoms	H1-receptor antagonist	Withdrawn due to concerns of arrhythmias	7.562	yes	8.538
Tolterodine	Overactive bladder	Muscarinic receptor antagonist	Approved	7.311	no	7.886
Droperidol	Nausea and vomiting in surgical and diagnostic procedures	Dopamine D2 receptor antagonist	Approved	7.300	yes	7.495
Dofetilide	Atrial fibrillation, atrial flutter	hERG channel blocker	Approved	7.164	yes	8.194
Haloperidol decanoate	Schizophrenia, psychotic disorders, Tourette’s disorder	Dopamine D2 receptor antagonist	Approved	7.149	no	6.921
Amiodarone	Recurrent ventricular fibrillation, recurrent hemodynamically unstable ventricular tachycardia	hERG channel blocker	Approved	7.127	yes	7.523
Terfenadine	Allergic rhinitis, hay fever, allergic skin disorders	H1-receptor antagonist	Withdrawn due to concerns of arrhythmias	7.022	yes	7.252

^aInformation regarding the pharmacological indication, mechanism of action, and FDA approval status for each drug is obtained from DrugBank [132, 133]

^bExperimentally determined hERG pIC₅₀ values are obtained from the hERG dataset curated by Arab et al. [41]